| Name | PARP-1-IN-3 |
| Description | PARP-1-IN-3 is a potent PARP-1 inhibitor that inhibits PARP-1 and PARP-2 with IC50 values of 0.25 nM and 2.34 nM, respectively.PARP-1-IN-3 has potential anti-inflammatory activity, induces apoptosis, and arrests the cell cycle in the G2/M phase.PARP-1-IN-3 may be useful for the study of cancer-related diseases. cancer-related diseases. |
| In vitro | PARP-1-IN-3 (compound 13f) demonstrates effective anticancer activity with IC50 values of 0.30 μM, 2.83 μM, 33.69 μM, and 486.87 μM against HCT116, DLD-1, SW480, and NCM460 cells, respectively, following a 48-hour treatment[1]. In HCT116 cells, PARP-1-IN-3 (0.3-3 μM) inhibits colony formation and migration over 24-48 hours[1]. A 48-hour treatment with PARP-1-IN-3 (0.3-3 μM) induces the accumulation of DNA double-strand breaks in HCT116 cells[1]. Treatment with PARP-1-IN-3 (0.3-7.5 μM) for 48-72 hours results in cell cycle arrest at the G2/M phase, reduced mitochondrial membrane potential, and apoptosis in HCT116 cells[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (235.14 mM), Sonication is recommended.
|
| Keywords | PARP1 | Apoptosis |
| Inhibitors Related | Stavudine | Cysteamine hydrochloride | Sodium 4-phenylbutyrate | Metronidazole | Citric Acid Triammonium | Tributyrin | L-Methionine | Sodium citrate | Cystamine dihydrochloride | L-Ascorbic acid sodium salt | Alginic acid | Dextran sulfate sodium salt (MW 5000) |
| Related Compound Libraries | Apoptosis Compound Library | DNA Damage & Repair Compound Library | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
